肿瘤相关性贫血的治疗进展

Treatment progress of cancer-related anemia

肿瘤相关性贫血(CRA)是肿瘤患者在疾病发生、发展及治疗过程中出现的一种并发症。有研究显示,非血液恶性肿瘤患者的贫血发生率大约40%,在肿瘤放化疗过程中,发生率可达到54%。CRA的发病机制尚未完全明确,国内外的研究也非常有限,CRA患者的生命质量及预后较差。在我国,由于经济水平及医疗条件发展的不平衡,导致不同级别医疗单位的医生对CRA的了解和重视水平参差不齐。因此,加强CRA的规范化诊治显得尤为重要。现有的治疗方法在疗效和安全性上均存在一定的局限性,新的治疗方法尚处于研究阶段,文章就CRA的诊断和治疗现状进行综述。

Cancer-related anemia(CRA)is a complication of tumor patients in the development and treatment of diseases.Studies have shown that the incidence of anemia in non-hematologic malignancies is about 40%,and the incidence can reach 54%during tumor radiotherapy and chemotherapy.The pathogenesis of CRA has not been fully clarified,and studies at home and abroad are also very limited.The quality of life and prognosis of CRA patients are poor.In China,due to the imbalance of economic level and the development of medical conditions,doctors in different levels of medical units have different levels of understanding and attention to CRA.Therefore,it is particularly important to strengthen the standardized diagnosis and treatment of CRA.The effectiveness and safety of the presently accepted therapeutic approaches are defined.The new treatment methods are still in the research stage.The article reviews the status of diagnosis and treatment of CRA.